NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACTIVASE (t-pa) INFUSION PROTOCOL FOR ACUTE MYOCARDIAL INFARCTION

Similar documents
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS

ACCESS CENTER:

CLINICAL GUIDELINES ID TAG

Primary Stroke Center Acute Stroke Transfer Guidelines When to Consider a Transfer:

How to give thrombolysis in acute myocardial infarction

Management of Acute Myocardial Infarction

ST Elevation Myocardial Infarction (STEMI) Reperfusion Order Set

NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS EPTIFIBATIDE (INTEGRILIN) PROTOCOL

ST Elevated Myocardial Infarction- Latest AHA recommendations

Is Thrombolysis Only for a Crisis?

9/24/2013. Thrombolytics in 2013: Never Say Never. September 19 th, 2013 Scott M Lilly, MD PhD. Clinical Case

When the learner has completed this module, she/he will be able to:

ASSESS OPPORTUNITIES TO IDENTIFY MISSED ELIGIBLE PATIENTS KEY QUESTIONS TO CONSIDER What are the top reasons for non-treatment? Are patients excluded

Thrombolysis administration

GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE

* * FORM REV. 02/2019 Page 1 of 4. TNKASE (tenecteplase) / ACUTE STEMI ORDERS SCHEDULED MEDICATIONS:

Thrombolysis for acute ischaemic stroke Rapid Assessment Protocol NORTHERN IRELAND Regional Protocol (Version 002 July 08)

Nursing Process Focus: Patients Receiving Heparin

Alliance A Symptomatic brain radionecrosis after receiving radiosurgery for

o Unenhanced Head CT

Nitroglycerin and Heparin Drip Interfacility Protocols

Diagnosis and Management of Acute Myocardial Infarction

BEAUMONT HOSPITAL. Beaumont Hospital Department of Nephrology and Renal Nursing ADMINISTRATION OF ACTILYSE. Guideline Number: 13. Guideline Version: B

Protocol for IV rtpa Treatment of Acute Ischemic Stroke

Considering Activase (alteplase) for treatment of acute ischemic stroke

Thrombolysis Assessment

ED Stroke Panel Page 1 of 2

The Multi arm Optimization of Stroke Thrombolysis (MOST) Trial

RETAVASE (reteplase) for injection, for intravenous use Initial U.S. Approval: 1996

ADVERSE REACTIONS The most frequently occurring adverse reaction ( > 5%) is bleeding.

Routine, Every 2 hours, Starting today, If temperature greater than 38.5 C initiate Evaluation for Possible Sepsis Physician Order #829

Venous Thromboembolism Prophylaxis

Objectives. Treatment of ACS. Early Invasive Strategy. UA/NSTEMI General Concepts. UA/NSTEMI Initial Therapy/Antithrombotic

Primary Stroke Center Quality & Performance Measures

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival

Critical Review Form Therapy

PE Pathway. The charts are listed as follows:

Results of Ischemic Heart Disease

Thrombolytic therapy should be the first line treatment in acute ishchemic stroke. We are against it!!

Administering Intravenous Alteplase (Tissue Plasminogen Activator [tpa])

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents

Activase (alteplase) for injection, for intravenous use Initial U.S. Approval: RECENT MAJOR CHANGES

Acute Stroke Protocols Modified- What s New in 2013

Resident Teaching Conference 3/12/2010

METALYSE Tenecteplase

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4

P-RMS: LT/H/PSUR/0004/001

2019 Home Hemodialysis Standing Orders

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Problems with Cardiac and Tissue Perfusion

Emergency Department Management of Acute Ischemic Stroke

Inhixa (Enoxaparin Sodium)

2018 Early Management of Acute Ischemic Stroke Guidelines Update

Supplementary Online Content

Present-on-Admission (POA) Coding

VENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

IR Central Venous Access [ ] Pre Procedure

Section 6 Intra Aortic Balloon Pump

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs

The first 24 hours are critical when Activase (alteplase) is administered 1-3

Thrombolysis in Acute Myocardial Infarction

DRUG GUIDELINE. HYDRALAZINE (Intravenous severe hypertension in pregnancy)

Canadian Stroke Best Practices Initial ED Evaluation of Acute Stroke and Transient Ischemic Attack (TIA) Order Set (Order Set 1)

Emergency Treatment of Ischemic Stroke

After a stroke starts

Updated Ischemic Stroke Guidelines นพ.ส ชาต หาญไชยพ บ ลย ก ล นายแพทย ทรงค ณว ฒ สาขาประสาทว ทยา สถาบ นประสาทว ทยา กรมการแพทย กระทรวงสาธารณส ข

Disclosures. Outline. Updated Recommendations for Using Alteplase (TPA) in Acute Ischemic Stroke

Policy REVISED: 6/30/2016 3:30 PM. Applies To: ObGyn Responsible Department: ObGyn Revised: June 30, 2016

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

convey the clinical quality measure's title, number, owner/developer and contact

VTE Prophylaxis. NEW NICE guidance. Providing venous thromboembolism (VTE) prophylaxis to all at risk hospital patients

Link between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.

Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy

BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine

Complications of Acute Myocardial Infarction

Acute Coronary Syndrome

Special Article. on Thrombolytic Therapy in Thrombosis,

PE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP

Thrombolysis, adjunctive pharmacology and interventions

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

CLINICAL PHARMACOLOGY

Pathophysiology of stroke

It is what you will see most in practice and what you need to know thoroughly.

Recent Changes in IV TPA Recommendations. Ashish Masih, M.D Vascular Neurology

Myocardial infarction

2.5 Other Hematology Consult:

Orthopedic Admission Hip Fracture Version 2 1/25/2017

Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis

Warfarin - Introduction for New Users

NUH Emergency Department. Guideline for Diagnosis & Treatment of PE (Massive and Non-Massive) in Adults only

Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:

Dr Ben Turner. Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital

Epidemiology: Incidence VTE: Mortality Morbidity Risk Factors: Acute Chronic : Genetic

Chp. 5 The cardiovascular system. What are the function of the cardiovascular system? Arteries and arterioles:

University of Wisconsin - Madison Cardiovascular Medicine Fellowship Program UW CCU Rotation Goals and Objectives Goals

Standardize comprehensive care of the patient with severe traumatic brain injury

Transcription:

NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS ACTIVASE (t-pa) FOR ACUTE MYOCARDIAL INFARCTION I. PURPOSE: A. To reduce the extent of myocardial infarction by lysing the clot in the coronary artery, salvaging the myocardium and preserving ventricular function. B. To reduce morbidity and mortality in acute myocardial infarction. II. PATIENT SELECTION: A. The patient must manifest the clinical signs and symptoms of acute myocardial infarction including typical electrocardiographic changes of acute injury. III. CONTRAINDICATIONS: A. Uncontrolled hypertension with systolic blood pressure of more than 180 mmhg, diastolic blood pressure of more than 110 mmhg. B. Recent CVA, intracranial neoplasm, AV malformation and aneurysm. C. Recent (within two months) intracranial or spinal injury, trauma or surgery. D. Pregnancy Date of Original: 1/85 Reviewed Revised 3/97 3/08 3/08 10/1 10/10 9/11 9/11 9/13 7-9-14 7-9-14 10/14 10/15 10/16 6/17 17

t-pa (ACTIVASE) E. Contraindication to anticoagulation. 1. Active internal bleeding including G.I., G.U. bleed, dissecting aortic aneurysm. 2. Bleeding diathesis. 3. Recent (within ten days) trauma or major surgery, including coronary artery bypass surgery, intra-abdominal surgery, organ biopsy, obstetrical delivery, prolonged traumatic external cardiac compression, traumatic endotracheal intubation, etc. IV. RELATIVE CONTRAINDICATIONS: A. Recent puncture of non-compressible blood vessel, i.e., subclavian vein, etc. B. Advanced liver and kidney disease. C. Infectious endocarditis. D. Pericarditis. E. Known or high likelihood of left heart thrombus. F. Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions. G. Septic thrombophlebitis or occluded AV cannula at seriously infected site. H. Patients currently receiving oral anticoagulants, i.e., warfarin sodium. I. Active peptic ulcer disease. V. PROCEDURE: A. The patient and/or patient s family should be well informed by the physician of the potential complications of acute thrombolytic therapy including bleeding complications. B. I.V. t-pa should be infused as soon as possible after the diagnosis of acute myocardial infarction is established. Any physician may prescribe I.V. t-pa, however, a cardiology consultation is recommended. 17a

C. Initial diagnostic work-up (STAT): 1. CBC and differential 2. Protime and PTT 3. Thrombin time 4. Fibrinogen 5. Blood typing 6. Routine CCU lab 7. EKG on admission and immediately before the procedure. D. Insert two peripheral venous lines in different arms, one in a large peripheral vein for I.V. t-pa infusion, the other for infusion of drugs. A separate heparin lock will be inserted for blood sampling. E. Patient may be given Lidocaine at the discretion of the physician. F. I.V. t-pa administration: Follow reconstitution directions for 100 mg dose vial. 1. Accelerated dose: For patients weighing more than 67kg: 15mg/BOLUS (15cc over 1-2 min.) 50mg/30 min. (Rate 100cc/hr, volume to be infused = 50mg) 35mg/60 min. (Rate 35cc/hr, volume to be infused = 35 mg) TOTAL: 100 mg/90 min. (t-pa I.V. bolus may be given by R.N.) 17b

2. Accelerated dose: For patients weighing less than 67 kg: 15 mg BOLUS - 0.75mg/kg/30 min. - 0.5mg/kg/60 min.) See scale below. WGT. IN LBS. WGT. IN KGS. 15 MG. BOLUS TOTAL MG. FOR MAINTEN- ANCE 0.75 MG/KG 20 MIN INF RATE 0.5 MG/KG 60 MIN INF RATE TOTAL DOSE 90-94 95-97 98-104 105-109 110-114 115-119 120-124 125-129 130-134 135-139 140-144 145-149 150-154 155-159 160-Up 41 43 45 48 50 52 55 57 59 61 64 66 68 70 15ml. 52 mg. 54 mg. 57 mg. 60 mg. 63 mg. 65 mg. 68 mg. 71 mg. 73 mg. 76 mg. 80 mg. 83 mg. 84 mg. 85 mg. 85 mg. 62 ml/hr 64 ml/hr 68 ml/hr 72 ml/hr 75 ml/hr 78 ml/hr 82 ml/hr 86 ml/hr 88 ml/hr 92 ml/hr 96 ml/hr 99 ml/hr 21 ml/hr 22 ml/hr 23 ml/hr 23 ml/hr 25 ml/hr 26 ml/hr 27 ml/hr 28 ml/hr 29 ml/hr 30 ml/hr 32 ml/hr 33 ml/hr 34 ml/hr 35 ml/hr 35 ml/hr 67 mg. 69 mg. 72 mg. 75 mg. 78 mg. 80 mg. 83 mg. 86 mg. 88 mg. 91 mg. 95 mg. 98 mg. 99 mg. 100 mg. 100 mg. G. Administration of I.V. Heparin with I.V. t-pa infusion is recommended. The dosage of Heparin to be given is at the discretion of the Physician. The suggested dose of Heparin is 5,000 units I.V. bolus (given concurrently with the t-pa) followed by 1,000 units per hour with subsequent dose adjustments to maintain PTT 46-70 seconds. I.V. heparin is recommended for at least 48 hours. (Heparin must be given through a separate I.V. site than Activase). H. Hold all venipuncture sites for at least five minutes. I. Test all stools for occult blood. H & H and PTT should be checked q 6 hours for at least 24 hours or at the discretion of the physician. J. Strict bed rest for 24 hours. 17c

K. Blood pressure should be monitored at least every 15 minutes during t-pa administration and the patient should be observed carefully for bleeding complications. L. Follow strict anticoagulation precaution protocol. 17d